Congresses

The materials posted below may contain scientific information about approved products, investigational product candidates that are not approved for any use in any country, or investigational uses of approved products. These materials are not intended to be, and should not be construed as, the marketing or promotion of any products or product candidates of Viela Bio.

09.2020

Inebilizumab

Pharmacodynamic modeling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders

ECTRIMS/ACTRIMS 2020

Congresses

Pharmacodynamic modeling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders

Serum neurofilament light chain levels correlate with attack-related disability in neuromyelitis optica spectrum disorder

Quiescent MRI activity in neuromyelitis optica spectrum disorder: results from the N-MOmentum randomized placebo-controlled trial

AQP4-IgG seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder

Serum Glial Fibrillary Acidic Protein Is Elevated in a Subset of Neuromyelitis Optica Patients and Associated with Increased Risk of Attacks

Inebilizumab Reduces Neuromyelitis Optica Spectrum Disorder Disability Worsening: Outcomes and Long-Term Follow-up Data from the N-MOmentum Trial

Long-term Efficacy and Safety of Inebilizumab for Neuromyelitis Optica Spectrum Disorder in the Randomized, Double-blind N-MOmentum Study and Extension

The N-MOmentum Study--A Randomised, Placebo-Controlled, Double-Blind Trial of Inebilizumab for Neuromyelitis Optica Spectrum Disorder: Randomised Controlled Period and Open-label Extension Results

Elevated serum glial fibrillary acidic protein (sGFAP) is associated with increased risk of neuromyelitis optica spectrum disorder attacks in the N-MOmentum randomised, masked, placebo-controlled clinical trial of inebilizumab

Sensitivity analyses of time to adjudicated attacks in the N-MOmentum study: a randomized, placebo-controlled, double-masked trial in patients with neuromyelitis optica spectrum disorder

Inebilizumab reduces worsening of disability in neuromyelitis optica spectrum disorder: outcomes from the N-MOmentum randomized, placebo-controlled, double-masked trial.

Characterization of B-cell subset changes following treatment of neuromyelitis optica spectrum disorder (NMOSD) with inebilizumab: results from the N-MOmentum study

Diagnosis, severity, and recovery of attacks in the N-MOmentum study of inebilizumab in neuromyelitis optica spectrum disorder

Randomized, double-masked, placebo-controlled trial of inebilizumab in neuromyelitis optica spectrum disorder

Randomized, double-masked, placebo-controlled trial of inebilizumab in neuromyelitis optica spectrum disorder